InMed Pharmaceuticals Inc. (INM) NASDAQ

2.51

-0.1599(-5.99%)

Updated at July 30 03:06PM

Currency In USD

InMed Pharmaceuticals Inc.

Address

815 West Hastings Street

Vancouver, BC V6C 1B4

Canada

Phone

604 669 7207

Sector

Healthcare

Industry

Biotechnology

Employees

13

First IPO Date

May 05, 2014

Key Executives

NameTitlePayYear Born
Mr. Eric A. Adams B.S. Chem., M.I.B.President, Chief Executive Officer & Director367,6001963
Dr. Sazzad Hossain M.Sc., Ph.D.Co-Founder132,3501959
Ms. N. Netta JagpalChief Financial Officer & Corporate Secretary261,0511973
Ms. Alexandra Diane-Janet Mancini M.Sc.Senior Vice President of Clinical & Regulatory Affairs297,8001953
Dr. Eric Chih-Hsien Hsu Ph.D.Senior Vice President of Preclinical Research & Development306,7001970
Mr. Michael Woudenberg P.Eng.Chief Operating Officer326,4001969
Dr. Ado MuhammadSenior Consultant of Medical Affairs0N/A
Colin ClancySenior Director of Investor Relations0N/A
Mr. Jerry P. GriffinVice President of Sales & Marketing0N/A
Dr. Shane A. Johnson Ph.D.Senior Vice President & GM of BayMedica0N/A

Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.